NEOG Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $209 million, up 0.3% year-over-year on a core basis.

Adjusted EBITDA: $35.5 million, representing a margin of 17%.

Adjusted Net Income: $9 million, or $0.04 per share, down from $14 million and $0.07 in the prior year.

Free Cash Flow: Outflow of $13 million, an improvement of $43 million compared to the prior year, driven by lower CapEx and better working capital efficiency.

Gross Margin: 45.4%, showing sequential improvement but impacted by inventory write-offs and higher operating expenses.

2Strategic Updates and Business Highlights

New CEO Mike Nassif emphasized the need for operational and financial improvement, focusing on top-line growth, cost management, innovation, and deleveraging.

A global headcount reduction of approximately 10% is expected to reduce operating expenses by $20 million annually, with some reinvestment planned for growth initiatives.

The company is optimizing its product portfolio and targeting higher growth markets, particularly in the U.S.

Significant efforts are underway to improve the PetriFilm production process, with initial testing showing promising results.

The integration of the sample collection product line is being prioritized to address cash flow challenges.

3Forward Guidance and Outlook

Neogen reaffirmed its full-year guidance for fiscal 2026, anticipating a modest sequential revenue increase in Q2.

The company expects improved EBITDA margins as operational efficiencies are realized and cost reductions take effect.

Management is optimistic about future revenue growth driven by enhanced commercial efforts and innovation focus.

4Bad News, Challenges, or Points of Concern

Market Share Losses: Neogen has experienced share losses in key product lines, particularly in sample collection and allergens, attributed to execution challenges and supply chain issues.

PetriFilm Decline: The product line saw a mid-single-digit revenue decline, which management believes is temporary due to distributor changes.

Inventory Management Issues: Elevated inventory write-offs and spoilage remain a concern, with excess inventory tying up cash.

Operational Inefficiencies: Challenges in sample collection production have resulted in higher costs and negative cash flow, although improvements are expected.

5Notable Q&A Insights

CEO Mike Nassif expressed confidence in Neogen's potential, citing a strong employee commitment and a broad product portfolio in an attractive market.

Nassif highlighted the need for improved execution and accountability to regain market share and drive growth.

CFO Dave Naemura provided clarity on the impact of inventory and operational challenges on margins, indicating a path toward recovery as improvements are implemented.

The company is continuously evaluating its portfolio for optimization opportunities, with a focus on food safety and animal safety products. Overall, while Neogen faces significant operational challenges and market share losses, the new leadership is committed to a focused strategy aimed at driving growth and improving financial performance.